Ibotenic acid and thioibotenic acid: A remarkable difference in activity at group III metabotropic glutamate receptors

European Journal of Pharmacology

Volumn 486, Issue 3, 2004, Pages 241-250

  Hermit, Mette B ^a   Greenwood, Jeremy R ^a   Nielsen, Birgitte ^a   Bunch, Lennart ^a   Jørgensen, Charlotte G ^a   Vestergaard, Henrik T ^a   Stensbøl, Tine B ^b   Sanchez, Connie ^b   Krogsgaard Larsen, Povl ^a   Madsen, Ulf ^a   Bräuner Osborne, Hans ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b H LUNDBECK A S   (Denmark)

Author keywords

Conformational energy; Docking; Glutamate receptor; Group III agonist; Homology model; Ibotenic acid; mGlu receptor; Thioibotenic acid

Indexed keywords

IBOTENIC ACID; ISOTHIAZOLE DERIVATIVE; METABOTROPIC RECEPTOR 3; THIOIBOTENIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CHO CELL; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG CONFORMATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ENERGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

EID: 10744221953     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2003.12.033     Document Type: Article

References (60)

1. 2+ signal transduction. J. Biol. Chem. 267:1992;13361-13368.
2. Aramori I., Nakanishi S. Signal transduction and pharmacological characteristics of a metabotropic glutamate receptor, mGluR1, in transfected CHO cells. Neuron. 8:1992;757-765.
3. Arnt J., Sanchez C., Lenz S.M., Madsen U., Krogsgaard-Larsen P. Differentiation of in vivo effects of AMPA and NMDA receptor ligands using drug discrimination methods and convulsant/anticonvulsant activity. Eur. J. Pharmacol. 285:1995;289-297.
4. Becke A.D. Density-functional thermochemistry: III. The role of exact exchange. J. Chem. Phys. 98:1993;5648-5652.
5. Bischoff F., Johansen T.N., Ebert B., Krogsgaard-Larsen P., Madsen U. Excitatory amino acid receptor ligands: asymmetric synthesis, absolute stereochemistry and pharmacology of (R)- and (S)-homoibotenic acid. Bioorg. Med. Chem. 3:1995;553-558.
6. Boström J., Norrby P.-O., Liljefors T. Conformational energy penalties of protein-bound ligands. J. Comput.-Aided Mol. Des. 12:1998;383-396.
7. 3H]kainic acid receptor binding by divalent cations correlates with ion affinity for the calcium channel. Neuropharmacology. 26:1987;1247-1251.
8. Bräuner-Osborne H., Krogsgaard-Larsen P. Pharmacology of (S)-homoquisqualic acid and (S)-2-amino-5-phosphonopentanoic acid [(S)-AP5] at cloned metabotropic glutamate receptors. Br. J. Pharmacol. 123:1998;269-274.
9. Bräuner-Osborne H., Nielsen B., Krogsgaard-Larsen P. Molecular pharmacology of homologues of ibotenic acid at cloned metabotropic glutamic acid receptors. Eur. J. Pharmacol. 350:1998;311-316.
10. Bräuner-Osborne H., Egebjerg J., Nielsen E.Ø., Madsen U., Krogsgaard-Larsen P. Ligands for glutamate receptors: design and therapeutic prospects. J. Med. Chem. 43:2000;2609-2645.
11. Brehm L., Frydenvang K., Krogsgaard-Larsen P., Liljefors T. Crystal structure and quantum chemical ab initio calculations of ibotenic acid, and excitatory amino acid receptor agonist. Struct. Chem. 9:1998;145-155.
12. Bruno V., Battaglia G., Ksiazek I., van der Putten H., Catania M.V., Giuffrida R., Lukic S., Leonhardt T., Inderbitzin W., Gasparini F., Kuhn R., Hampson D.R., Nicoletti F., Flor P.J. Selective activation of mGlu4 metabotropic glutamate receptors is protective against excitotoxic neuronal death. J. Neurosci. 20:2000;6413-6420.
13. Bunch L., Krogsgaard-Larsen P., Madsen U. Regioselective lithiation and functionalization of 3-(benzyloxy)isothiazole: application to the synthesis of thioibotenic acid. J. Org. Chem. 67:2002;2375-2377.
14. Cancès E., Mennucci B. Comment on "Reaction field treatment of charge penetration" J. Chem. Phys. 114:2001;4744-4745.
15. Chahine M., Bennett P.B., George A.L. Jr., Horn R. Functional expression and properties of the human skeletal muscle sodium channel. Pflugers Arch. 427:1994;136-142.
16. Cheng Y., Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22:1973;3099-3108.
17. Clausen R.P., Bräuner-Osborne H., Greenwood J.R., Hermit M.B., Stensbøl T.B., Nielsen B., Krogsgaard-Larsen P. Selective agonists at group II metabotropic glutamate receptors: synthesis, stereochemistry, and molecular pharmacology of (S)- and (R)-2-amino-4-(4-hydroxy[1,2,5]thiadiazol-3- yl)butyric acid. J. Med. Chem. 45:2002;4240-4245.
18. Conn P.J., Pin J.P. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 37:1997;205-237.
19. Dingledine R., Borges K., Bowie D., Traynelis S.F. The glutamate receptor ion channels. Pharmacol. Rev. 51:1999;7-61.
20. Eijkenboom M., Blokland A., van der Staay F.J. Modelling cognitive dysfunctions with bilateral injections of ibotenic acid into the rat entorhinal cortex. Neuroscience. 101:2000;27-39.
21. Frydenvang K., Matzen L., Norrby P.-O., Sløk F.A., Liljefors T., Krogsgaard-Larsen P., Jaroszewski J.W. Structural characteristics of isoxazol-3-ol and isothiazol-3-ol, carboxy group bioisosteres examined by X-ray crystallography and ab initio calculations. J. Chem. Soc., Perkin Trans. 2:1997;1783-1791.
22. Gerlai R., Roder J.C., Hampson D.R. Altered spatial learning and memory in mice lacking the mGluR4 subtype of metabotropic glutamate receptor. Behav. Neurosci. 112:1998;525-532.
23. Goodford P.J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. 28:1985;849-857.
24. Haley T.J., McCormick W.G. Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br. J. Pharmacol. 12:1957;12.
25. Halgren T.A. MMFF VI. MMFF94s option for energy minimization studies. J. Comput. Chem. 20:1999;720-729.
26. Halgren T.A. MMFF VII. Characterization of MMFF94, MMFF94s, and other widely available force fields for conformational energies and for intermolecular-interaction energies and geometries. J. Comput. Chem. 20:1999;730-748.
27. Harrison N.L., Simmonds M.A. Quantitative studies on some antagonists of N-methyl D-aspartate in slices of rat cerebral cortex. Br. J. Pharmacol. 84:1985;381-391.
28. Hayashi Y., Tanabe Y., Aramori I., Masu M., Shimamoto K., Ohfune Y., Nakanishi S. Agonist analysis of 2-(carboxycyclopropyl) glycine isomers for cloned metabotropic glutamate receptor subtypes expressed in Chinese hamster ovary cells. Br. J. Pharmacol. 107:1992;539-543.
29. Hayashi Y., Momiyama A., Takahashi T., Ohishi H., Ogawa-Meguro R., Shigemoto R., Mizuno N., Nakanishi S. Role of a metabotropic glutamate receptor in synaptic modulation in the accessory olfactory bulb. Nature. 366:1993;687-690.
30. Henrich-Noack P., Flor P.J., Sabelhaus C.F., Prass K., Dirnagl U., Gasparini F., Sauter A., Rudin M., Reymann K.G. Distinct influence of the group III metabotropic glutamate receptor agonist (R,S)-4-phosphonophenylglycine [(R,S)-PPG] on different forms of neuronal damage. Neuropharmacology. 39:2000;911-917.
31. Holscher C., Gigg J., O'Mara S.M. Metabotropic glutamate receptor activation and blockade: their role in long-term potentiation, learning and neurotoxicity. Neurosci. Biobehav. Rev. 23:1999;399-410.
32. Honore T., Nielsen M. Complex structure of quisqualate-sensitive glutamate receptors in rat cortex. Neurosci. Lett. 54:1985;27-32.
33. Jarrard L.E. Use of excitotoxins to lesion the hippocampus: update. Hippocampus. 12:2002;405-414.
34. Jorgensen W.L., Maxwell D.S., Tirado-Rives J. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J. Am. Chem. Soc. 118:1996;11225-11235.
35. 35S]GTPgammaS binding assessment of metabotropic glutamate receptor standards in Chinese hamster ovary cell lines expressing the human metabotropic receptor subtypes 2 and 4. Neuropharmacology. 37:1998;179-187.
36. Krishnan R., Binkley J.S., Seeger R., Pople J.A. Self-consistent molecular orbital methods: XX. A basis set for correlated wave functions. J. Chem. Phys. 72:1980;650.
37. Krogsgaard-Larsen P., Hansen J.J. Naturally-occurring excitatory amino acids as neurotoxins and leads in drug design. Toxicol. Lett. 64-65:1992;409-416.
38. Krogsgaard-Larsen P., Honore T., Hansen J.J., Curtis D.R., Lodge D. New class of glutamate agonist structurally related to ibotenic acid. Nature. 284:1980;64-66.
39. Kunishima N., Shimada Y., Tsuji Y., Sato T., Yamamoto M., Kumasaka T., Nakanishi S., Jingami H., Morikawa K. Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature. 407:2000;971-977.
40. Lacroix L., Spinelli S., White W., Feldon J. The effects of ibotenic acid lesions of the medial and lateral prefrontal cortex on latent inhibition, prepulse inhibition and amphetamine-induced hyperlocomotion. Neuroscience. 97:2000;459-468.
41. Lu Y.M., Jia Z., Janus C., Henderson J.T., Gerlai R., Wojtowicz J.M., Roder J.C. Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP. J. Neurosci. 17:1997;5196-5205.
42. Lu J., Zhang Y.H., Chou T.C., Gaus S.E., Elmquist J.K., Shiromani P., Saper C.B. Contrasting effects of ibotenate lesions of the paraventricular nucleus and subparaventricular zone on sleep-wake cycle and temperature regulation. J. Neurosci. 21:2001;4864-4874.
43. Madsen U., Frølund B., Lund T.M., Ebert B., Krogsgaard-Larsen P. Design, synthesis and pharmacology of model compounds for indirect elucidation of the topography of AMPA receptor sites. Eur. J. Med. Chem. 28:1993;791-800.
44. Madsen U., Dumpis M.A., Bräuner-Osborne H., Piotrovsky L.B. Synthesis and pharmacology of N-alkylated derivatives of the excitotoxin ibotenic acid. Bioorg. Med. Chem. Lett. 8:1998;1563-1568.
45. Madsen U., Bräuner-Osborne H., Frydenvang K., Hvene L., Johansen T.N., Nielsen B., Sanchez C., Stensbøl T.B., Bischoff F., Krogsgaard-Larsen P. Synthesis and pharmacology of 3-isoxazolol amino acids as selective antagonists at group I metabotropic glutamic acid receptors. J. Med. Chem. 44:2001;1051-1059.
46. Mathiesen J.M., Svendsen N., Bräuner-Osborne H., Thomsen C. Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB 1893 and MPEP. Br. J. Pharmacol. 138:2003;1026-1030.
47. Matzen L., Ebert B., Stensbøl T.B., Frølund B., Jaroszewski J.W., Krogsgaard Larsen P. Bioisosterically modified dipeptide excitatory amino acid receptor antagonists containing 3-oxygenated isothiazole ring systems. Bioorg. Med. Chem. 5:1997;1569-1575.
48. Matzen L., Engesgaard A., Ebert B., Didriksen M., Frølund B., Krogsgaard-Larsen P., Jaroszewski J.W. AMPA receptor agonists: synthesis, protolytic properties, and pharmacology of 3-isothiazolol bioisosteres of glutamic acid. J. Med. Chem. 40:1997;520-527.
49. Monastyrskaia K., Lundstrom K., Plahl D., Acuna G., Schweitzer C., Malherbe P., Mutel V. Effect of the umami peptides on the ligand binding and function of rat mGlu4a receptor might implicate this receptor in the monosodium glutamate taste transduction. Br. J. Pharmacol. 128:1999;1027-1034.
50. Monn J.A., Valli M.J., Massey S.M., Hansen M.M., Kress T.J., Wepsiec J.P., Harkness A.R., Grutsch J.L., Wright R.A., Johnson B.G., Andis S.L., Kingston A., Tomlinson R., Lewis R., Griffey K.R., Tizzano J.P., Schoepp D.D. Synthesis, pharmacological characterization, and molecular modeling of heterocyclic amino acids related to (+)-2-aminobicyclo[3.1.0]hexane-2,6- dicarboxylic acid (LY354740): identification of two new potent, selective and systemically active agonists for group II metabotropic glutamate receptors. J. Med. Chem. 42:1999;1027-1040.
51. Motulsky H., Neubig R. Analyzing radioligand binding data. Crawley J., Gerfen C., McKay R., Rogawski M., Sibley D., Skolnic P. Current Protocols in Neuroscience. 1997;7.5.1-7.5.56 John Wiley & Sons Inc. New York.
52. Nakanishi S. Molecular diversity of glutamate receptors and implications for brain function. Science. 258:1992;597-603.
53. Naples M.A., Hampson D.R. Pharmacological profiles of the metabotropic glutamate receptor ligands. Neuropharmacology. 40:2001;170-177.
54. Pagano A., Rovelli G., Mosbacher J., Lohmann T., Duthey B., Stauffer D., Ristig D., Schuler V., Meigel I., Lampert C., Stein T., Prezeau L., Blahos J., Pin J., Froestl W., Kuhn R., Heid J., Kaupmann K., Bettler B. C-terminal interaction is essential for surface trafficking but not for heteromeric assembly of GABA(b) receptors. J. Neurosci. 21:2001;1189-1202.
55. 3H]MK-801 binding to the N-methyl-D-aspartate receptor-ion channel complex by L-glutamate, glycine, and polyamines. J. Neurochem. 51:1988;830-836.
56. Schwede T., Diemand A., Guex N., Peitsch M.C. Protein structure computing in the genomic era. Res. Microbiol. 151:2000;107-112.
57. 3H]CGP 39653: a new N-methyl-D-aspartate antagonist radioligand with low nanomolar affinity in rat brain. Eur. J. Pharmacol. 192:1991;19-24.
58. Tanabe Y., Masu M., Ishii T., Shigemoto R., Nakanishi S. A family of metabotropic glutamate receptors. Neuron. 8:1992;169-179.
59. Tanabe Y., Nomura A., Masu M., Shigemoto R., Mizuno N., Nakanishi S. Signal transduction, pharmacological properties, and expression patterns of two rat metabotropic glutamate receptors, mGluR3 and mGluR4. J. Neurosci. 13:1993;1372-1378.
60. Turner J.J., Hodges H., Sinden J.D., Gray J.A. Comparison of radial maze performance of rats after ibotenate and quisqualate lesions of the forebrain cholinergic projection system: effects of pharmacological challenge and changes in training regime. Behav. Pharmacol. 3:1992;359-373.